Skip to main content Skip to navigation
Hamburger Menu
Search icon
Country Selector Country Selector
Germany (English)
Profile Icon Profile Icon
Sign-in/Register UserName
Products

Solutions

Discover & Learn

Resources & Tools

Support

Search icon Search icon
Close Menu
      Alert Icon
      BUV661 Mouse Anti-Human CD105 (Endoglin)

      BD OptiBuild™ BUV661 Mouse Anti-Human CD105 (Endoglin)

      Clone SN6h (also known as SN6H; G4-2C2)

      (RUO)
      View all Formats
      Product Details
      Down Arrow Up Arrow


      BD OptiBuild™
      END; endoglin; HHT1; ORW1
      Human (Tested in Development)
      Mouse BALB/c IgG1, κ
      Endoglin from Human Acute Lymphoblastic Leukemia Cells
      Flow cytometry (Qualified)
      0.2 mg/ml
      VI E109
      Aqueous buffered solution containing ≤0.09% sodium azide.
      RUO


      Preparation And Storage

      Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
      Show More blue down arrow Show Less blue up arrow

      Recommended Assay Procedures

      BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation).  When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells.   However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls.  It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.

      For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime BD Horizon Brilliant dyes are used in a multicolor flow cytometry panel.  Fluorescent dye interactions may cause staining artifacts which may affect data interpretation.  The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. When BD Horizon Brilliant Stain Buffer is used in in the multicolor panel, it should also be used in the corresponding compensation controls for all dyes to achieve the most accurate compensation. For the most accurate compensation, compensation controls created with either cells or beads should be exposed to BD Horizon Brilliant Stain Buffer for the same length of time as the corresponding multicolor panel. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).

      Note:  When using high concentrations of antibody, background binding of this dye to erythroid cell subsets (mature erythrocytes and precursors) has been observed.  For researchers studying these cell populations, or in cases where light scatter gating does not adequately exclude these cells from the analysis, this background may be an important factor to consider when selecting reagents for panel(s).

      Show More blue down arrow Show Less blue up arrow

      Product Notices

      1. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
      2. Researchers should determine the optimal concentration of this reagent for their individual applications.
      3. An isotype control should be used at the same concentration as the antibody of interest.
      4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
      5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
      6. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
      7. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
      8. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
      9. BD Horizon Brilliant Ultraviolet 661 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,575,303; 8,354,239.
      10. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
      Show More blue down arrow Show Less blue up arrow
      753549 Rev. 1
      Antibody Details
      Down Arrow Up Arrow
      SN6h

      The SN6h monoclonal antibody specifically recognizes CD105. CD105 is a type I transmembrane glycoprotein that is encoded by END (Endoglin) and belongs to the transforming growth factor-β (TGF-β) type III receptor family. CD105 (Endoglin) is expressed on cells as a homodimer comprised of ~95 kDa subunits. It is expressed on vascular endothelial cells and placental syncytiotrophoblasts and at lower levels on stromal fibroblasts. CD105 (Endoglin) is also expressed on mesenchymal stem cells, erythroid precursors, monocytes, macrophages, pre-B cells, and some tumor cells and cell lines including U937 cells. CD105 (Endoglin) serves as a regulatory component of the TGF-β receptor system. In association with TGF- βRI or TGF- βRII, CD105 (Endoglin) binds TGF-β1 and TGF-β3 with high affinity but does not bind to TGF-β2. Expression of CD105 (Endoglin) is increased on activated endothelium in tissues undergoing angiogenesis, such as in tumors, or in cases of wound healing or dermal inflammation.

      753549 Rev. 1
      Format Details
      Down Arrow Up Arrow
      BUV661
      The BD Horizon Brilliant™ Ultraviolet 661 (BUV661) Dye is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This tandem fluorochrome is comprised of a BUV395 donor with an excitation maximum (Ex Max) of 350-nm and an acceptor dye with an emission maximum (Em Max) at 660-nm. BUV661, driven by BD innovation, is designed to be excited by the ultraviolet laser (355-nm) and detected using an optical filter centered near 660-nm (e.g., 670/25 bandpass filter). The acceptor dye can be excited by the Red (628–640-nm) laser resulting in cross-laser excitation and fluorescence spillover. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
      BUV661
      Ultraviolet 355 nm
      350 nm
      660 nm
      753549 Rev.1
      Citations & References
      Down Arrow Up Arrow
      View product citations for antibody "753549" on CiteAb

      Development References (5)

      1. Mutin M, Dignat-George F, Sampol J. Immunologic phenotype of cultured endothelial cells: quantitative analysis of cell surface molecules.. Tissue Antigens. 1997; 50(5):449-58. (Clone-specific: Flow cytometry). View Reference
      2. Schoonderwoerd MJA, Goumans MTH, Hawinkels L. Endoglin: Beyond the Endothelium. Biomolecules. 2020; 10:1-17. (Biology). View Reference
      3. Seon BK, Matsuno F, Haruta Y, Barcos M, Spaulding B. CD105 Workshop: immunohistochemical detection of CD105 in the vascular endothelium of human malignant and non-malignant tissues. In: Kishimoto T. Tadamitsu Kishimoto .. et al., ed. Leucocyte typing VI : white cell differentiation antigens : proceedings of the sixth international workshop and conference held in Kobe, Japan, 10-14 November 1996. New York: Garland Pub.; 1997:709–710.
      4. She X, Matsuno F, Harada N, Tsai H, Seon BK. Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells.. Int J Cancer. 2004; 108(2):251-7. (Immunogen: Immunoprecipitation, Radioimmunoassay). View Reference
      5. Takahashi N, Kawanishi-Tabata R, Haba A, et al. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin.. Clin Cancer Res. 2001; 7(3):524-32. (Clone-specific: Flow cytometry). View Reference
      View All (5) View Less
      753549 Rev. 1

      Please refer to Support Documents for Quality Certificates


      Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


      Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

      For Research Use Only. Not for use in diagnostic or therapeutic procedures.